2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Stomach Neoplasms
7
Esophageal Neoplasms
4
Gastrointestinal Neoplasms
3
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Adenocarcinoma
2
Solid Tumor
1
Rectal Neoplasms
1
Patients With Advanced or Metastatic Solid Tumors
1
Pathologic Complete Response
1
Neoplasms, Unknown Primary
1
Nasopharyngeal Carcinoma
1
Locally Advanced Gastric Adenocarcinoma
1
Hand-Foot Syndrome
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Biliary Tract Neoplasms
1
Bile Duct Neoplasms
1
Adenocarcinoma Of Esophagus
1
Interventions
Fluorouracil
219
Leucovorin
202
Oxaliplatin
192
Irinotecan
150
Bevacizumab
110
Capecitabine
94
Cetuximab
90
Folfox protocol
54
Chemotherapy, Adjuvant
36
Panitumumab
30
Colonoscopy
30
pembrolizumab
23
Drug Therapy
23
Nivolumab
22
Magnetic Resonance Spectroscopy
22
Gemcitabine
21
Blood Specimen Collection
20
Radiotherapy
19
Floxuridine
19
Biopsy
19
Neoadjuvant Therapy
18
Laparoscopy
18
IFL protocol
18
Early Intervention, Educational
18
Celecoxib
18
Surveys and Questionnaires
17
Surgical Procedures, Operative
16
Immunohistochemistry
16
Exercise
16
trifluridine tipiracil drug combination
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Colonic Neoplasms
×
tegafur-gimeracil-oteracil
×
Clear all
NCT02216149
2018-08-28
FluoHeart
Helsinki University Central Hospital
Phase 2
Terminated
20 enrolled